Clinical trials: B-Non Hodgkin Lymphoma
Leukemia, Lymphoma
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Background: Leukapheresis is a procedure to separate and collect white blood cells. It is the first step in a treatment called CAR (chimeric antigen receptor) T-cell therapy.
- Conditions
- Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03226704
- Testing
- Leukapheresis
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900484
- Testing
- biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 191 sites in United States
- Volunteers
- 458 people
- Sponsor
- SWOG Cancer Research Network
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia
- Trial name
- NCT04191187
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lymphoma, Lymphoma, B-Cell
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
This research study combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been…
- Conditions
- Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03696784
- Testing
- iC9-CAR19 T cells, Bendamustine, Fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas.
- Trial name
- V+DA-EPOCH-R (NCT03036904)
- Testing
- Venetoclax, Rituximab, Etoposide
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Weill Medical College of Cornell University
Leukemia, Lymphocytic, Acute
Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
B cell acute lymphoblastic leukemia (B-ALL)/Lymphoblastic lymphoma (LBL) is a hematological malignancy caused by malignant transformation and clonal expansion of B-lineage precursor cells.
- Trial name
- ZJU-HSCT-INO (NCT06861348)
- Testing
- Inotuzumab Ozogamicin±Donor Lymphocyte Infusion
- Where
- China
- Volunteers
- 23 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
B-Cell Non-Hodgkin Lymphoma, Multiple Myeloma
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to standard of care (SOC) in…
- Trial name
- NCT06052826
- Testing
- Best Practice, Cognitive Intervention, Comprehensive Geriatric Assessment
- Where
- 4 sites in United States
- Volunteers
- 164 people
- Sponsor
- City of Hope Medical Center
Richter's Syndrome
Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome
The purpose of this study is to evaluate Ofatumumab in combination with CHOP (cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and prednisone/prednisolone, the standard chemotherapy treatment) in…
- Trial name
- CHOP-OR (NCT01171378)
- Testing
- Ofatumumab
- Where
- 9 sites in United Kingdom
- Volunteers
- 43 people
- Sponsor
- University of Oxford
B Cell Lymphoma, Acute Lymphoblastic Leukemia
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of anti-CD22 CAR-T cells in patients with relapsed or refractory B-cell Malignancies.
- Trial name
- NCT04007978
- Testing
- Third generation CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Non-Hodgkin Lymphoma
PIC1 Injection Therapy for Relapsed/Refractory B-NHL
This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma.
- Trial name
- NCT07456371
- Testing
- PIC1 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.
- Trial name
- NCT05794958
- Testing
- Axicabtagene Ciloleucel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
DLBCL, Diffuse Large B-Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the…
- Trial name
- NCT05139017
- Testing
- Zilovertamab vedotin, Rituximab, Gemcitabine
- Where
- 135 sites in United States, Argentina and 24 more
- Volunteers
- 290 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°)
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
The goal of this study is to evaluate efficacy and safety of the combination of lenalidomide, an immunomodulatory drug (IMiD) with a standard immunochemotherapy treatment, called R-DHAP.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant, Burkitt Lymphoma (BL)
- Trial name
- R²-DHAP (NCT02983097)
- Testing
- Rituximab, Cisplatin, Carboplatin
- Where
- 12 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
B-Cell Leukemia, Non-Hodgkin's Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies.
- Conditions
- B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06208735
- Testing
- CLIC-2201
- Where
- 7 sites in Canada
- Volunteers
- 24 people
- Sponsor
- British Columbia Cancer Agency
B-Cell Lymphoma
High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
A prospective pilot trial was proposed to patients with DLBCL, with IH or high adjusted IPI, up to the age of 60 y.o. This program consisted of 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose…
- Trial name
- NCT00965289
- Testing
- Rituximab
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Nantes University Hospital
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
This phase II trial studies how well giving rituximab together with combination chemotherapy works in treating patients with previously untreated high- or high-intermediate-risk diffuse large B-cell lymphoma (DLBCL).
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT01539174
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
The purpose of this study is to evaluate the safety, tolerability and clinical activity of RO6870810 in combination with venetoclax and when co-administered with rituximab in participants with relapse/refractory (R/R) diffuse…
- Trial name
- NCT03255096
- Testing
- RO6870810, Venetoclax, Rituximab
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 39 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B Cell Lymphoma
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
This is an exploratory study embedded in the Phase Ib/II clinical trial of CD3 x 4-1BB x CD19 x PD-L1 tetra-specific T cell engager GNC-038 in relapsed and refractory diffuse large B-cell lymphoma initiated by the corresponding…
- Trial name
- NCT05189782
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Ruijin Hospital
Graft Versus Host Disease, Leukemia
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00608517
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoma, Large B-Cell, Diffuse
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, and predictive biomarkers of durvalumab in combination with R-CHOP or R2-CHOP, followed by durvalumab consolidation therapy in…
- Trial name
- NCT03003520
- Testing
- Durvalumab, Rituximab, Doxorubicin
- Where
- 20 sites in United States, Austria and 3 more
- Volunteers
- 46 people
- Sponsor
- Celgene